News
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate ...
New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...
Eli Lilly (NYSE: LLY) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding ...
Everyday Health on MSN6h
Dementia Takes More Than 3 Years to Diagnose, Research FindsEarly dementia signs can resemble the normal cognitive changes of aging. But timely diagnosis can help people get the ...
Zacks Investment Research on MSN18h
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?Eli Lilly and Company LLY will report its second-quarter earnings on Aug. 7, before market open. The Zacks Consensus Estimate ...
The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback